ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 185 filers reported holding ASCENDIS PHARMA A/S in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $672,054 | +18.3% | 7,177 | +12.8% | 0.04% | +21.6% |
| Q2 2023 | $567,897 | -8.9% | 6,363 | +9.4% | 0.04% | -14.0% |
| Q1 2023 | $623,591 | -7.7% | 5,816 | +5.2% | 0.04% | -15.7% |
| Q4 2022 | $675,256 | +21.4% | 5,529 | +2.5% | 0.05% | +10.9% |
| Q3 2022 | $556,000 | +11.4% | 5,393 | +0.4% | 0.05% | -8.0% |
| Q2 2022 | $499,000 | -20.8% | 5,369 | 0.0% | 0.05% | -7.4% |
| Q1 2022 | $630,000 | -25.0% | 5,369 | -14.1% | 0.05% | -21.7% |
| Q4 2021 | $840,000 | +9.8% | 6,251 | +30.1% | 0.07% | +9.5% |
| Q3 2021 | $765,000 | +21.2% | 4,804 | 0.0% | 0.06% | 0.0% |
| Q2 2021 | $631,000 | +14.7% | 4,804 | +12.4% | 0.06% | +6.8% |
| Q1 2021 | $550,000 | +1.1% | 4,275 | +30.9% | 0.06% | -11.9% |
| Q4 2020 | $544,000 | +30.1% | 3,267 | +20.6% | 0.07% | +11.7% |
| Q3 2020 | $418,000 | +11.5% | 2,710 | +6.7% | 0.06% | +1.7% |
| Q2 2020 | $375,000 | +83.8% | 2,540 | +39.6% | 0.06% | +47.5% |
| Q1 2020 | $204,000 | – | 1,820 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |